The American Hospital Association, the Maine Hospital Association and four hospitals filed an Oct. 9 lawsuit to block HRSA's revised 340B rebate pilot in a Maine federal district court.
Novo's blockbuster GLP-1 drug Ozempic/Wegovy/Rybelus is one of two eligible drugs that was not included in HRSA's recent 340B rebate model plan approvals.
The Ohio Department of Health recently released detailed, individual 340B covered entity reports based on a provider reporting law enacted last summer.
